MedPath

ode study: 'Esophageal resection for patients with esophageal cancer and cervical lymph node metastases'

Phase 2
Recruiting
Conditions
esophageal cancer with cervical lymphnode metastasis
10017990
10017991
10017998
Registration Number
NL-OMON44167
Lead Sponsor
Heelkunde, chirurgie
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

- Histologically proven squamous cell carcinoma or adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus.
- Surgical resectable carcinoma (T1-4a, N1-3)
- Histologically/ cytologically proven resectable cervical lymph node metastases level III and/ or IV
- Age >= 18
- European Clinical Oncology Group (ECOG) performance status 0,1 or 2
- Written informed consent

Exclusion Criteria

- Distant metastases
- Esophageal carcinoma < 3 cm beneath UES
- Carcinoma of the gastro-esophageal junction (GEJ) with major tumor in the gastric cardia (Siewert III)
- Former radiotherapy or chemotherapy for esophageal carcinoma
- Former radiotherapy precluding radiotherapy according the CROSS protocol
- Inadequate pulmonary function disabling transthoracic resection
- Previous neck dissection
- New York heart association class III/IV and no history of active angina. Patients with a history of significant ventricular arrhythmia requiring medication or congestive heart failure. History of 2nd or 3rd degree heart blocks

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcome is the percentage of overall postoperative complications grade<br /><br>3b and higher as stated by the modified Clavien-Dindo classification (MCDC).</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary outcomes are individual components of the primary outcome,<br /><br>complications grade 2 and 3a, mortality, operation related events and<br /><br>postoperative recovery including quality of life, disease free survival, 5 year<br /><br>overall survival and if applicable location of recurrent disease.</p><br>
© Copyright 2025. All Rights Reserved by MedPath